|
Status |
Public on May 11, 2020 |
Title |
Gene expression in response to knockdown of GLI1. |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by high throughput sequencing
|
Summary |
GLI1 is a transcription factor correlated to decreased survival in several cancers. We have identified SMARCA2 as a co-regulator that enhances GLI1-mediated transcriptional activity and functions through the C-terminal transcriptional activation domain of GLI1. Central domains including the ATPase motif of SMARCA2 physically interact with GLI1. Evaluation of DNA density indicates GLI1, like SMARCA2, can increase the DNA accessibility with a preference for sites distal to gene transcription start sites and outside the promoter regions (i.e. enhancers). The putative enhancers where accessibility is decreased by the knock down of GLI1 and SMARCA2 are located cis to genes, such as HHIP, that are regulated by GLI1 and implicated in cancer functions. At the putative enhancer for HHIP, the localization of SMARCA2 is at least partially dependent on GLI1’s presence. Understanding this transcriptional regulation by GLI1 and SMARCA2 through altering chromatin accessibility at enhances can provide additional therapeutic targets for cancers dependent on GLI1.
|
|
|
Overall design |
Gene expression was measured in RMS13 cells following the siRNA knockdown of GLI1.
|
|
|
Contributor(s) |
Safgren SL, Gaspar-Maia A, Fernandez-Zapico ME |
Citation(s) |
32376693 |
|
Submission date |
Jan 14, 2020 |
Last update date |
Jun 04, 2020 |
Contact name |
Stephanie Lynn Safgren |
E-mail(s) |
safgren.stephanie@mayo.edu
|
Organization name |
Mayo Clinic
|
Department |
Oncology Research
|
Lab |
Martin E. Fernandez-Zapico
|
Street address |
200 1st Street SW, Gonda 19 366C
|
City |
Rochester |
State/province |
Minnesota |
ZIP/Postal code |
55920 |
Country |
USA |
|
|
Platforms (1) |
GPL20301 |
Illumina HiSeq 4000 (Homo sapiens) |
|
Samples (6)
|
|
Relations |
BioProject |
PRJNA601227 |
SRA |
SRP241956 |